Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The artificial intelligence (AI) boom has taken the stock market by storm. The S&P 500 (SNPINDEX: ^GSPC) has advanced 55% in ...

Vertex Global Services partners with Arish Global Services to create 5,000 jobs in Delhi-NCR, focusing on business process ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Arish Global Services has emerged as one of the leading providers in web lead generation, offering a comprehensive suite of ...

Google has unveiled a detailed whitepaper on the development and functionality of Generative AI agents. Google unveils ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

While you may be going booze-free to start the year, that doesn’t mean you can’t jazz up your non-alcoholic drinks.